{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:06:33Z","timestamp":1794960393704,"version":"4.9.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Global Initiative for Asthma (GINA) was established in 1993 by the World Health Organization and the US National Heart Lung and Blood Institute to improve asthma awareness, prevention and management worldwide. GINA develops and publishes evidence-based, annually updated resources for clinicians. GINA guidance is adopted by national asthma guidelines in many countries, adapted to fit local healthcare systems, practices, and resource availability. GINA is independent of industry, funded by the sale and licensing of its materials. This review summarizes key practical guidance for primary care from the 2022 GINA strategy report. It provides guidance on confirming the diagnosis of asthma using spirometry or peak expiratory flow. GINA recommends that all adults, adolescents and most children with asthma should receive inhaled corticosteroid (ICS)-containing therapy to reduce the risk of severe exacerbations, either taken regularly, or (for adults and adolescents with \u201cmild\u201d asthma) as combination ICS\u2013formoterol taken as needed for symptom relief. For patients with moderate\u2013severe asthma, the preferred regimen is maintenance-and-reliever therapy (MART) with ICS\u2013formoterol. Asthma treatment is not \u201cone size fits all\u201d; GINA recommends individualized assessment, adjustment, and review of treatment. As many patients with difficult-to-treat or severe asthma are not referred early for specialist review, we provide updated guidance for primary care on diagnosis, further investigation, optimization and treatment of severe asthma across secondary and tertiary care. While the GINA strategy has global relevance, we recognize that there are special considerations for its adoption in low- and middle-income countries, particularly the current poor access to inhaled medications.<\/jats:p>","DOI":"10.1038\/s41533-023-00330-1","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:24:36Z","timestamp":1675841076000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":332,"title":["Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-3246","authenticated-orcid":false,"given":"Mark L.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Bacharier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5064-5849","authenticated-orcid":false,"given":"Eric","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3485-9393","authenticated-orcid":false,"given":"Louis-Philippe","family":"Boulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Brusselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro A.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Drazen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Duijts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-7433","authenticated-orcid":false,"given":"Louise","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-3812","authenticated-orcid":false,"given":"Hiromasa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-0087","authenticated-orcid":false,"given":"Fanny W. S.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-4778","authenticated-orcid":false,"given":"Jerry A.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8118-8871","authenticated-orcid":false,"given":"Kevin","family":"Mortimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7319-1133","authenticated-orcid":false,"given":"Paulo M.","family":"Pitrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-0944","authenticated-orcid":false,"given":"Arzu","family":"Yorganc\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6695-6350","authenticated-orcid":false,"given":"Helen K.","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"330_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1183\/20734735.008914","volume":"11","author":"ML Levy","year":"2015","unstructured":"Levy, M. L. The national review of asthma deaths: what did we learn and what needs to change? Breathe 11, 15\u201324 (2015).","journal-title":"Breathe"},{"key":"330_CR2","unstructured":"Royal College of Physicians. Why Asthma Still Kills. The National Review of Asthma Deaths (NRAD) Confidential Enquiry Report (RCP, 2014)."},{"key":"330_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4104\/pcrj.2011.00097","volume":"21","author":"K Anagnostou","year":"2012","unstructured":"Anagnostou, K., Harrison, B., Iles, R. & Nasser, S. Risk factors for childhood asthma deaths from the UK Eastern Region Confidential Enquiry 2001\u20132006. Prim. Care Respir. J. 21, 71\u201377 (2012).","journal-title":"Prim. Care Respir. J."},{"key":"330_CR4","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/bmj.285.6350.1251","volume":"285","author":"British Thoracic Association.","year":"1982","unstructured":"British Thoracic Association. Death from asthma in two regions of England. British Thoracic Association. Br. Med. J. 285, 1251\u20131255 (1982).","journal-title":"Br. Med. J."},{"key":"330_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.5588\/ijtld.22.1010","volume":"26","author":"Global Asthma Network.","year":"2022","unstructured":"Global Asthma Network. The Global Asthma Report 2022. Int. J. Tuberc. Lung Dis. 26, S1\u2013S102 (2022).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"330_CR6","doi-asserted-by":"publisher","first-page":"2103179","DOI":"10.1183\/13993003.03179-2021","volume":"60","author":"K Mortimer","year":"2022","unstructured":"Mortimer, K., Reddel, H. K., Pitrez, P. M. & Bateman, E. D. Asthma management in low- and middle-income countries: case for change. Eur. Respir. J. 60, 2103179 (2022).","journal-title":"Eur. Respir. J."},{"key":"330_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S0140-6736(21)00458-X","volume":"397","author":"J Meghji","year":"2021","unstructured":"Meghji, J. et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet 397, 928\u2013940 (2021).","journal-title":"Lancet"},{"key":"330_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.5588\/ijtld.22.0270","volume":"26","author":"M Stolbrink","year":"2022","unstructured":"Stolbrink, M. et al. Improving access to affordable quality-assured inhaled medicines in low- and middle-income countries. Int. J. Tuberc. Lung Dis. 26, 1023\u20131032 (2022).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"330_CR9","doi-asserted-by":"crossref","unstructured":"World Health Organization. Model List of Essential Medicines. 22nd list (2021) (WHO, 2021).","DOI":"10.1530\/ey.19.13.1"},{"key":"330_CR10","doi-asserted-by":"publisher","first-page":"1901046","DOI":"10.1183\/13993003.01046-2019","volume":"53","author":"HK Reddel","year":"2019","unstructured":"Reddel, H. K. et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur. Respir. J. 53, 1901046 (2019).","journal-title":"Eur. Respir. J."},{"key":"330_CR11","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2022 (GINA, 2022)."},{"key":"330_CR12","unstructured":"Global Asthma Network. The Global Asthma Report 2018 (Global Asthma Network, 2018)."},{"key":"330_CR13","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1164\/rccm.201804-0682CI","volume":"198","author":"SD Aaron","year":"2018","unstructured":"Aaron, S. D., Boulet, L. P., Reddel, H. K. & Gershon, A. S. Underdiagnosis and overdiagnosis of asthma. Am. J. Respir. Crit. Care Med. 198, 1012\u20131020 (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"330_CR14","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1503\/cmaj.081332","volume":"179","author":"SD Aaron","year":"2008","unstructured":"Aaron, S. D. et al. Overdiagnosis of asthma in obese and nonobese adults. CMAJ 179, 1121\u20131131 (2008).","journal-title":"CMAJ"},{"key":"330_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/thoraxjnl-2019-213068","volume":"75","author":"DK Lo","year":"2020","unstructured":"Lo, D. K. et al. Lung function and asthma control in school-age children managed in UK primary care: a cohort study. Thorax 75, 101\u2013107 (2020).","journal-title":"Thorax"},{"key":"330_CR16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1136\/thorax.55.7.562","volume":"55","author":"CP van Schayck","year":"2000","unstructured":"van Schayck, C. P., van Der Heijden, F. M., van Den Boom, G., Tirimanna, P. R. & van Herwaarden, C. L. Underdiagnosis of asthma: is the doctor or the patient to blame? The DIMCA project. Thorax 55, 562\u2013565 (2000).","journal-title":"Thorax"},{"key":"330_CR17","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/thorax.58.10.846","volume":"58","author":"RJ Adams","year":"2003","unstructured":"Adams, R. J. et al. Underdiagnosed asthma in South Australia. Thorax 58, 846\u2013850 (2003).","journal-title":"Thorax"},{"key":"330_CR18","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1183\/09031936.00002108","volume":"32","author":"PL Brand","year":"2008","unstructured":"Brand, P. L. et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach [European Respiratory Society Task Force]. Eur. Respir. J. 32, 1096\u20131110 (2008).","journal-title":"Eur. Respir. J."},{"key":"330_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJM199501193320301","volume":"332","author":"FD Martinez","year":"1995","unstructured":"Martinez, F. D. et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N. Engl. J. Med. 332, 133\u2013138 (1995).","journal-title":"N. Engl. J. Med."},{"key":"330_CR20","doi-asserted-by":"publisher","first-page":"575.e2","DOI":"10.1016\/j.jaci.2013.05.041","volume":"132","author":"DCM Belgrave","year":"2013","unstructured":"Belgrave, D. C. M. et al. Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing. J. Allergy Clin. Immunol. 132, 575.e2\u2013583.e2 (2013).","journal-title":"J. Allergy Clin. Immunol."},{"key":"330_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jaci.2012.05.007","volume":"130","author":"OE Savenije","year":"2012","unstructured":"Savenije, O. E., Kerkhof, M., Koppelman, G. H. & Postma, D. S. Predicting who will have asthma at school age among preschool children. J. Allergy Clin. Immunol. 130, 325\u2013331 (2012).","journal-title":"J. Allergy Clin. Immunol."},{"key":"330_CR22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJM200008033430504","volume":"343","author":"S Suissa","year":"2000","unstructured":"Suissa, S., Ernst, P., Benayoun, S., Baltzan, M. & Cai, B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 343, 332\u2013336 (2000).","journal-title":"N. Engl. J. Med."},{"key":"330_CR23","first-page":"CD013518","volume":"5","author":"I Crossingham","year":"2021","unstructured":"Crossingham, I. et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst. Rev. 5, CD013518 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"330_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2147\/JAA.S176026","volume":"11","author":"DB Price","year":"2018","unstructured":"Price, D. B. et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J. Asthma Allergy 11, 193\u2013204 (2018).","journal-title":"J. Asthma Allergy"},{"key":"330_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1164\/ajrccm.153.1.8542164","volume":"153","author":"MD Inman","year":"1996","unstructured":"Inman, M. D. & O\u2019Byrne, P. M. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am. J. Respir. Crit. Care Med. 153, 65\u201369 (1996).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"330_CR26","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1164\/ajrccm.156.6.96-08042","volume":"156","author":"GM Gauvreau","year":"1997","unstructured":"Gauvreau, G. M., Jordana, M., Watson, R. M., Cockroft, D. W. & O\u2019Byrne, P. M. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am. J. Respir. Crit. Care Med. 156, 1738\u20131745 (1997).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"330_CR27","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1183\/09031936.94.07091602","volume":"7","author":"S Suissa","year":"1994","unstructured":"Suissa, S., Blais, L. & Ernst, P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur. Respir. J. 7, 1602\u20131609 (1994).","journal-title":"Eur. Respir. J."},{"key":"330_CR28","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1007\/s12325-020-01444-5","volume":"37","author":"CI Bloom","year":"2020","unstructured":"Bloom, C. I. et al. Asthma-related health outcomes associated with short-acting \u03b2(2)-agonist inhaler use: an observational UK study as part of the SABINA Global Program. Adv. Ther. 37, 4190\u20134208 (2020).","journal-title":"Adv. Ther."},{"key":"330_CR29","doi-asserted-by":"publisher","first-page":"1901872","DOI":"10.1183\/13993003.01872-2019","volume":"55","author":"BI Nwaru","year":"2020","unstructured":"Nwaru, B. I. et al. Overuse of short-acting \u03b22-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur. Respir. J. 55, 1901872 (2020).","journal-title":"Eur. Respir. J."},{"key":"330_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1001\/jama.2018.2769","volume":"319","author":"DM Sobieraj","year":"2018","unstructured":"Sobieraj, D. M. et al. Association of inhaled corticosteroids and long-acting \u03b2-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. JAMA 319, 1485\u20131496 (2018).","journal-title":"JAMA"},{"key":"330_CR31","doi-asserted-by":"crossref","unstructured":"Cates, C. J. & Karner, C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst. Rev. CD007313 (2013).","DOI":"10.1002\/14651858.CD007313.pub3"},{"key":"330_CR32","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/resp.13804","volume":"25","author":"CR Jenkins","year":"2020","unstructured":"Jenkins, C. R., Bateman, E. D., Sears, M. R. & O\u2019Byrne, P. M. What have we learnt about asthma control from trials of budesonide\/formoterol as maintenance and reliever? Respirology 25, 804\u2013815 (2020).","journal-title":"Respirology"},{"key":"330_CR33","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1378\/chest.130.6.1733","volume":"130","author":"H Bisgaard","year":"2006","unstructured":"Bisgaard, H. et al. Budesonide\/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 130, 1733\u20131743 (2006).","journal-title":"Chest"},{"key":"330_CR34","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1513\/AnnalsATS.202011-1386OC","volume":"18","author":"ED Bateman","year":"2021","unstructured":"Bateman, E. D. et al. Positioning as-needed budesonide-formoterol for mild asthma: effect of prestudy treatment in pooled analysis of SYGMA 1 and 2. Ann. Am. Thorac. Soc. 18, 2007\u20132017 (2021).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"330_CR35","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1715275","volume":"378","author":"ED Bateman","year":"2018","unstructured":"Bateman, E. D. et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N. Engl. J. Med. 378, 1877\u20131887 (2018).","journal-title":"N. Engl. J. Med."},{"key":"330_CR36","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1056\/NEJMoa1715274","volume":"378","author":"PM O\u2019Byrne","year":"2018","unstructured":"O\u2019Byrne, P. M. et al. Inhaled combined budesonide\u2013formoterol as needed in mild asthma. N. Engl. J. Med. 378, 1865\u20131876 (2018).","journal-title":"N. Engl. J. Med."},{"key":"330_CR37","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1901963","volume":"380","author":"R Beasley","year":"2019","unstructured":"Beasley, R. et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N. Engl. J. Med. 380, 2020\u20132030 (2019).","journal-title":"N. Engl. J. Med."},{"key":"330_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(19)31948-8","volume":"394","author":"J Hardy","year":"2019","unstructured":"Hardy, J. et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 394, 919\u2013928 (2019).","journal-title":"Lancet"},{"key":"330_CR39","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40264-020-01041-z","volume":"44","author":"JM FitzGerald","year":"2021","unstructured":"FitzGerald, J. M. et al. Safety of as-needed budesonide-formoterol in mild asthma: data from the two phase III SYGMA studies. Drug Saf. 44, 467\u2013478 (2021).","journal-title":"Drug Saf."},{"key":"330_CR40","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.jaip.2021.10.011","volume":"10","author":"HK Reddel","year":"2022","unstructured":"Reddel, H. K., Bateman, E. D., Schatz, M., Krishnan, J. A. & Cloutier, M. M. A practical guide to implementing SMART in asthma management. J. Allergy Clin. Immunol. Pract. 10, S31\u2013s38 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"330_CR41","doi-asserted-by":"crossref","unstructured":"Reddel, H. K. et al. Global Initiative for Asthma (GINA) Strategy 2021 \u2013 Executive summary and rationale for key changes. Eur. Respir. J. 59, 2102730 (2021).","DOI":"10.1183\/13993003.02730-2021"},{"key":"330_CR42","unstructured":"Terrence Carney. Regulation 28 statement in the matter of Tamara Mills (deceased). (2015)."},{"key":"330_CR43","unstructured":"Dr Shirley Radcliffe. Regulation 28 Statement in the matter of Sophie Holman (deceased). (2019)."},{"key":"330_CR44","unstructured":"Dr Shirley Radcliffe. Regulation 28 Statement in the matter of Michael Uriely (deceased). (2017)."},{"key":"330_CR45","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/JAA.S311721","volume":"14","author":"M Chan","year":"2021","unstructured":"Chan, M. et al. Assessment of variation in care following hospital discharge for children with acute asthma. J. Asthma Allergy 14, 797\u2013808 (2021).","journal-title":"J. Asthma Allergy"},{"key":"330_CR46","unstructured":"Royal College of Physicians. National Asthma and Chronic Obstructive Pulmonary Disease Audit Programme (NACAP) Children and Young People Asthma Audit 2019\/20 (Royal College of Physicians, 2021)."},{"key":"330_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(16)31399-X","volume":"389","author":"HK Reddel","year":"2017","unstructured":"Reddel, H. K. et al. Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. Lancet 389, 157\u2013166 (2017).","journal-title":"Lancet"},{"key":"330_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1398-9995.2007.01394.x","volume":"62","author":"D Dusser","year":"2007","unstructured":"Dusser, D. et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 62, 591\u2013604 (2007).","journal-title":"Allergy"},{"key":"330_CR49","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jaci.2014.08.042","volume":"135","author":"PP Hekking","year":"2015","unstructured":"Hekking, P. P. et al. The prevalence of severe refractory asthma. J. Allergy Clin. Immunol. 135, 896\u2013902 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"330_CR50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/02770903.2019.1672723","volume":"58","author":"CI Bloom","year":"2021","unstructured":"Bloom, C. I., Walker, S. & Quint, J. K. Inadequate specialist care referrals for high-risk asthma patients in the UK: an adult population-based cohort 2006\u20132017. J. Asthma 58, 19\u201325 (2021).","journal-title":"J. Asthma"},{"key":"330_CR51","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1136\/thoraxjnl-2013-204114","volume":"70","author":"S O\u2019Neill","year":"2015","unstructured":"O\u2019Neill, S. et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 70, 376\u2013378 (2015).","journal-title":"Thorax"},{"key":"330_CR52","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1155\/2010\/361071","volume":"17","author":"M Sadatsafavi","year":"2010","unstructured":"Sadatsafavi, M. et al. Direct health care costs associated with asthma in British Columbia. Can. Respir. J. 17, 74\u201380 (2010).","journal-title":"Can. Respir. J."},{"key":"330_CR53","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2500\/aap.2018.39.4183","volume":"39","author":"V Plaza","year":"2018","unstructured":"Plaza, V. et al. Impact of patient satisfaction with his or her inhaler on adherence and asthma control. Allergy Asthma Proc. 39, 437\u2013444 (2018).","journal-title":"Allergy Asthma Proc."},{"key":"330_CR54","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.rmed.2011.01.005","volume":"105","author":"AS Melani","year":"2011","unstructured":"Melani, A. S. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med. 105, 930\u2013938 (2011).","journal-title":"Respir. Med."},{"key":"330_CR55","doi-asserted-by":"publisher","first-page":"1071.e9","DOI":"10.1016\/j.jaip.2017.01.004","volume":"5","author":"DB Price","year":"2017","unstructured":"Price, D. B. et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J. Allergy Clin. Immunol. Pract. 5, 1071.e9\u20131081.e9 (2017).","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-023-00330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-023-00330-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-023-00330-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T00:09:29Z","timestamp":1676074169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-023-00330-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["330"],"URL":"https:\/\/doi.org\/10.1038\/s41533-023-00330-1","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"assertion":[{"value":"10 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.D. declares no competing interests. The other authors report the following conflicting interests (including financial and non-financial): M.L.L. has received consultancy fees from Clement Clarke International, Boehringer Ingelheim, AstraZeneca, GSK, Orion, TEVA pharmaceuticals, Menarini, NSHI, Chiesi Pharmaceuticals, Novartis, Aspire, Respiri Ltd (Australia), and Smart Respiratory Products Ltd, speaker fees from TEVA, Novartis, Orion, AstraZeneca, NAPP, Chiesi, and NSHI, and honoraria from ADMIT Group - Consorzio Ferrara Ricerche. M.L.L. is Editor Emeritus of <i>npj Primary Care Respiratory Medicine<\/i>, but was not involved in the journal\u2019s review of, or decisions related to, this manuscript. L.B.B. has received grants from NIH\/NIAID and NHLBI, personal fees from GlaxoSmithKline Genentech\/Novartis, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD\/Medscape, Sanofi, Regeneron, Vectura, Circassia, Kinaset, Vertex, and OM Pharma, and royalties from Elsevier outside the submitted work. E.B. has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Hikma pharma, Menarini, Novartis, Sanofi Genzyme, and Regeneron, and consulting fees from AstraZeneca, Sanofi Genzyme, Regeneron, and Novartis. L.-P.B. has received research grants for participation in multicenter studies from Amgen, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Sanofi-Regeneron, and BioHaven, research funding for projects introduced by the investigator from AstraZeneca, GlaxoSmithKline, and Merck, consulting and advisory board fees from Astra Zeneca, Novartis, GlaxoSmithKline, Merck, and Sanofi-Regeneron, lecture fees from AstraZeneca, Covis, Cipla, GlaxoSmithKline, Novartis and Merck, and Sanofi, and non-profit grants to produce educational materials from AstraZeneca, Covis, GlaxoSmithKline, Merck, and Novartis. C.B. has received consultancy fees or grants (paid to Institution) from GSK, AZ, BI, Novartis, Chiesi, Genentech, Roche, Sanofi, Regeneron, Mologic, and 4DPharma. G.B. has received speaker fees and advisory board fees from Astra Zeneca, Boehringer-Ingelheim, Chiesi, GSK, Merck Sharp & Dohme, Novartis, and Sanofi Regeneron. R.B. has received consulting fees or honoraria for lectures from ALK, AstraZeneca, Berlin-Chemie, Boehringer-Ingelheim, Chiesi, Cipla, GSK, Novartis, Roche, Sanofi, and TEVA, and grants to Mainz University Hospital for research or clinical trials, or both from Boehringer Ingelheim, GSK, Novartis, and Roche. A.A.C. has received consultancy and speaker fees from Abdi-Ibrahim, AstraZeneca, Boehringer-Ingelheim, Chiesi, Eurofarma, Glennmark, GSK, Novartis, and Sanofi. A.C.C. is a member of the Planning Group of the Global Alliance against Chronic Respiratory Diseases (GARD)\/WHO, and the Executive Director of ProAR Foundation \u2013 Brazil. L.D. has received grants from the European Union Horizon 2020 research and innovation program (LIFECYCLE, grant agreement No 733206, 2016; EUCAN-Connect grant agreement No 824989; ATHLETE, grant agreement No 874583) and Stichting Vrienden van Sophia, and speaker fee (paid to institute) from Hong Kong University. L.D. is Vice chair of the Dutch Pediatric Respiratory Society. L.F. has received personal fees from Novartis, Astra Zeneca, and Sanofi, outside the submitted work. H.I. has received speaker and advisory board fees from Astellas, AstraZeneca, Boehringer-Ingelheim, Fukuda-Denshi, GSK, Kracie, Kyorin, Novartis, Omron, Pfizer, and Sanofi, and research grants and support (paid to university) from Asahi-Kasei Pharma, AstraZeneca, Boehringer-Ingelheim, Chugai, GlaxoSmithKline, Kyorin, Otsuka, Teijin, Taiho, and Ono. F.W.S.K. has received funding for conducting multi-center research on asthma from the Hong Kong Thoracic Society (which was supported by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Novartis) with all fees paid directly to the institution. J.A.K. has received consulting fees from GlaxoSmithKline, AstraZeneca, and BData, Inc., and grants and contract fees from Regeneron (COVID-19 clinical trial), Sergey Bring Family Foundation (COVID-19 cohort study), Patient-Centered Outcomes Research Institute (research studies in asthma, COPD, insomnia), National Institutes of Health (research studies in asthma, COPD, acute COVID-19, and post-acute sequelae of SARS-CoV-2), and American Lung Association (asthma and COPD research). K.M. has received advisory board fees from AstraZeneca. P.M.P. has received consultancy and speaker fees from AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Novartis, and Sanofi. A.S. has advised AstraZeneca on an unremunerated basis and has received a research grant from GSK (COVID-19 therapeutics). A.S. is editor emeritus of npj PCRM but was not involved in the journal\u2019s review of, or decisions related to, this manuscript. A.Y. has received consultancy and speaker honoraria from Astra-Zeneca, Novartis, GSK, Chiesi, DEVA, and Abdi \u0130brahim. A.Y. is Chair of GARD. A.Y. is an editor for <i>npj Primary Care Respiratory Medicine<\/i> but was not involved in the journal\u2019s review of, or decisions related to, this manuscript. H.K.R. has received honoraria for participation in advisory boards for AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi-Genzyme; and from AstraZeneca, Boehringer Ingelheim, Chiesi, Getz, GlaxoSmithKline, Sanofi, and Teva Pharmaceuticals for independent medical educational presentations; she has received independent research funding from AstraZeneca, GlaxoSmithKline, and Novartis; and consulting fees from AstraZeneca and Novartis. L.P.B. (Chair), E.B., G.B., A.A.C., H.I., J.K., M.L.L., H.K.R., and A.Y. are members of Global Initiative for Asthma (GINA) Board of Directors. L.B., E.B., L.P.B., C.B., G.B., R.B., J.D., L.D., L.F., H.I., F.K., K.M., P.M.P., H.K.R. (Chair), A.S., and A.Y. are members of the GINA Science Committee. L.P.B., A.A.C., H.I., M.L.L. (Chair), and A.Y. are members of GINA Dissemination and Implementation Task Group.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}